FINWIRES · TerminalLIVE
FINWIRES

調査速報:CFRAはKenvue Inc.の株式について「ホールド」の見解を維持します。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。当社は、12ヶ月目標株価を19ドルに据え置きます。これは、2027年のEPS予想である1.15ドルの16.5倍に相当し、2023年の上場以来の株価収益率(PER)18.1倍を割安としています。このPERは、キンバリー・クラーク(KMB)による買収(2026年第2四半期に完了予定)に伴う訴訟リスクと、KVUEの単独業績に関する見通しの不透明さ(同社はもはや将来予測やアナリスト向け説明会を開催していない)を考慮すると、妥当であると考えています。本日発表された第1四半期決算を受け、2026年のEPS予想を1.10ドルから1.15ドルに引き上げます。2027年のEPS予想は1.15ドルで据え置きます。KVUEは堅調な第1四半期決算を発表し、事業の勢いが継続していることを示しました。純売上高は前年同期比4.5%増の39億900万ドルとなり、実質成長率は0.7%でした。この業績は、取引完了が近づくにつれ、経営陣の事業運営上の取り組みが成果を上げ始めていることを示唆しています。この取引は2026年1月に株主の承認を得ており、規制当局の承認手続きも進んでいます。

Related Articles

Insider Trading

Teva Pharmaceutical Industries Insider Sold Shares Worth $384,444, According to a Recent SEC Filing

Amir Weiss, Chief Accounting Officer, on May 06, 2026, sold 10,679 shares in Teva Pharmaceutical Industries (TEVA) for $384,444. Following the Form 4 filing with the SEC, Weiss has control over a total of 20,016 ordinary shares of the company, with 20,016 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/818686/000119312526211855/xslF345X05/ownership.xml

$TEVA
Research

Research Alert: CFRA Maintains Buy Opinion On Shares Of Doordash, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our price target by $2 to $240, based on 30x our 2027 EPS view, just below DASH's three-year average (~32x) given competitive threats from AI and Uber Eats, offset by the company's dominant market position and positive network effects. We raise our 2026 adjusted EPS view by $0.10 to $5.63 and 2027's by $0.06 to $7.99. We are encouraged by DASH's Q2 Marketplace GOV guidance (+36% Y/Y), an encouraging result following relatively soft guidance for Q1, especially given fears of a weakening consumer. International sales continue to scale solidly, with Deliveroo accelerating to 14% Y/Y growth in Q1 vs. 7% growth in Q4 (we expect continued improvement all year). Margin pressure remains (adjusted EBITDA margin -20 bps Y/Y to 2.4%) but should fade as platform integration activities finish up early next year. Adjusted EBITDA guidance (midpoint of $820M) was above expectations ($742M), despite the company expecting another $50M gas relief charge, which should persist amid the Strait of Hormuz closure.

$DASH
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Tyson Foods, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target remains $76, a 15x multiple of projected FY 27 EPS of $5.09 (raised by $0.02). We also lift our FY 26 (Sep.) EPS est. by $0.09 to $4.11. This multiple is slightly above TSN's long-term average of 14x, reflecting favorable secular tailwinds, including a continued shift in consumer preferences toward protein and improved earnings growth potential as the Beef segment recovers, likely in FY 27. Operationally, TSN is executing well, particularly in Chicken, where margins continue to widen, up 290 bps year over year in FQ2. Beef remains pressured by historically tight cattle supplies, with the U.S. herd at its lowest level since 1951, though we expect margins to improve following recent restructuring actions, including rightsizing production to improve capacity utilization. TSN's balance sheet is solid, noting its leverage ratio (net debt/adjusted EBITDA) has now improved to 2.2x vs. 3.9x two years ago. This provides a decent degree of financial flexibility in our view.

$TSN